Yutaka Kawakami

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 11

Top Topics

Vascular Endothelial Growth Factor

Top Venues

Experimental dermatology

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

The Journal of experimental medicine

Journal for immunotherapy of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Masahiro Toda, Yoshiharu Yamanobe, Masato Fujioka, Yukina Morimoto, Mariko Fukumura, Masato Nakaya, Yumiko Oishi, Mizuto Sato, Ryo Ueda, Hirokazu Fujiwara, Tetsuro Hikichi, Shinobu Noji, Naoki Oishi, Hiroyuki Ozawa, Kaoru Ogawa, Yutaka Kawakami, Takayuki Ohira, Kazunari Yoshida, Masahiro Toda
Phase I/II Study of a Vascular Endothelial Growth Factor Receptor Vaccine in Patients With NF2-Related Schwannomatosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (21) (2024)
Masahiro Toda, Yoshiharu Yamanobe, Masato Fujioka, Yukina Morimoto, Mariko Fukumura, Masato Nakaya, Yumiko Oishi, Mizuto Sato, Ryo Ueda, Hirokazu Fujiwara, Tetsuro Hikichi, Shinobu Noji, Naoki Oishi, Hiroyuki Ozawa, Kaoru Ogawa, Yutaka Kawakami, Takayuki Ohira, Kazunari Yoshida, Masahiro Toda
Phase I/II Study of a Vascular Endothelial Growth Factor Receptor Vaccine in Patients With NF2-Related Schwannomatosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (21) (2024)
Ryota Tamura, Yoshiharu Yamanobe, Masato Fujioka, Yukina Morimoto, Mariko Fukumura, Masato Nakaya, Yumiko Oishi, Mizuto Sato, Ryo Ueda, Hirokazu Fujiwara, Tetsuro Hikichi, Shinobu Noji, Naoki Oishi, Hiroyuki Ozawa, Kaoru Ogawa, Yutaka Kawakami, Takayuki Ohira, Kazunari Yoshida, Masahiro Toda
Phase I/II Study of a Vascular Endothelial Growth Factor Receptor Vaccine in Patients With NF2-Related Schwannomatosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Shigeki Ohta, Aya Misawa, Chaw Kyi-Tha-Thu, Naomi Matsumoto, Yoshie Hirose, Yutaka Kawakami
Melanoma antigens recognized by T cells and their use for immunotherapy. Experimental dermatology 32 (3) (2023)
Shigeki Ohta, Aya Misawa, Chaw Kyi-Tha-Thu, Naomi Matsumoto, Yoshie Hirose, Yutaka Kawakami
Melanoma antigens recognized by T cells and their use for immunotherapy. Experimental dermatology 32 (3) (2023)
Shigeki Ohta, Aya Misawa, Chaw Kyi-Tha-Thu, Naomi Matsumoto, Yoshie Hirose, Yutaka Kawakami
Melanoma antigens recognized by T cells and their use for immunotherapy. Experimental dermatology 32 (3) (2023)
Shigeki Ohta, Aya Misawa, Chaw Kyi-Tha-Thu, Naomi Matsumoto, Yoshie Hirose, Yutaka Kawakami
Melanoma antigens recognized by T cells and their use for immunotherapy. Experimental dermatology (2023)
Shigeki Ohta, Aya Misawa, Chaw Kyi-Tha-Thu, Naomi Matsumoto, Yoshie Hirose, Yutaka Kawakami
Melanoma antigens recognized by T cells and their use for immunotherapy. Experimental dermatology (2023)
Yukina Morimoto, Ayako Tokumitsu, Takefumi Sone, Yuki Hirota, Ryota Tamura, Ayuna Sakamoto, Kazunori Nakajima, Masahiro Toda, Yutaka Kawakami, Hideyuki Okano, Shigeki Ohta
TPT1 Supports Proliferation of Neural Stem/Progenitor Cells and Brain Tumor Initiating Cells Regulated by Macrophage Migration Inhibitory Factor (MIF). Neurochemical research 47 (9) (2022)
Yuki Katoh, Tomonori Yaguchi, Akiko Kubo, Takashi Iwata, Kenji Morii, Daiki Kato, Shigeki Ohta, Ryosuke Satomi, Yasuhiro Yamamoto, Yoshitaka Oyamada, Kota Ouchi, Shin Takahashi, Chikashi Ishioka, Ryo Matoba, Makoto Suematsu, Yutaka Kawakami
Inhibition of stearoyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating β-catenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 antibody. Journal for immunotherapy of cancer 10 (7) (2022)
Keitaro Fukuda, Ken Okamura, Rebecca L Riding, Xueli Fan, Khashayar Afshari, Nazgol-Sadat Haddadi, Sean Matthew McCauley, Mehmet Hakan Guney, Jeremy Luban, Takeru Funakoshi, Tomonori Yaguchi, Yutaka Kawakami, Anastasia Khvorova, Katherine A Fitzgerald, John E Harris
AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma. The Journal of experimental medicine 218 (9) (2021)